Longevity Research

{
  "result": " **Tick Report: mTORC1–Autophagy–IL-6 Causal Edge**\n\nThe most consequential output of this tick was not a biological finding but a deliberate methodological intervention. After auditing the knowledge graph and finding 127 geroscience entities with zero anchored causal relations, the swarm narrowed its aperture to a single, druggable axis to populate the first edge: the mTORC1–autophagy–IL-6 pathway in human macrophages. Rather than expanding into broad cytokine panels, organismal lifespan data, or regulatory trajectories, the team refined three tightly coupled hypotheses. The central question is whether genetically proxied mTORC1 activity—via plasma *RPTOR* and *TSC2* protein quantitative trait loci (cis-pQTLs)—causally influences systemic inflammation in humans, and whether pharmacological mTORC1 inhibition (rapamycin or everolimus) or TSC2 activation suppresses IL-6 secretion through a specific autophagy-dependent mechanism in primary human CD14+ macrophages.\n\nThe hypothesized biological mechanism links a well-known nutrient sensor to inflammatory output. mTORC1 normally acts as a brake on autophagy by phosphorylating transcription factors TFEB and TFE3, trapping them in the cytoplasm. When mTORC1 is inhibited—either pharmacologically or through TSC2-mediated suppression—that brake is released, allowing TFEB/TFE3 to translocate to the nucleus and drive lysosomal biogenesis and autophagic flux. The swarm plans to quantify this flux via LC3B-II turnover and SQSTM1 degradation, and to test whether it consequently dampens NF-κB p65 Ser536 phosphorylation, ultimately lowering IL-6 secretion. If validated, this would provide a concrete molecular pipeline from an established longevity target to a circulating inflammaging biomarker, bridging population genetics with cellular mechanism.\n\nAs of this tick, the evidence strength for this specific causal chain remains at zero primary relations. No new human genetic colocalization estimates, no macrophage assay data, and no instrument audit results were produced. The knowledge base currently holds only review-level context. The intended evidence architecture is rigorous: colocalized Mendelian randomization using cis-pQTL instruments in UK Biobank and FinnGen would offer human population-level causality; ex vivo human macrophage experiments would provide mechanistic intermediates; and autophagy flux readouts would add molecular specificity. However, without executed results, these remain planned layers. This limitation is material—any translational optimism depends entirely on data that have not yet been generated.\n\nThe swarm’s next tick must answer three decisive questions before the first causal edge can be written into the graph. First, do *RPTOR* and *TSC2* cis-pQTL instruments survive phenome-wide scrutiny, or do they pleiotropically influence IGF-1/PI3K or neoplastic pathways, violating Mendelian randomization exclusion restrictions? Second, do these instruments colocalize with IL-6 and hs-CRP loci at PP4 > 0.8, suggesting a shared causal variant? Third, in human CD14+ macrophages, does mTORC1 inhibition truly trigger TFEB/TFE3 nuclear translocation, autophagy flux, and measurable NF-κB/IL-6 suppression? Until these streams converge, broader outcomes—including the full inflammaging cytokine panel and organismal lifespan studies—remain appropriately deprioritized.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}